Wanbury, a pharmaceutical company, declared their Q3 FY24 results on 24 Jan, 2024. The topline increased by 15.68% compared to the previous year's same period.
In the previous fiscal year's same period, Wanbury had declared a loss of ₹3.28Cr, making the current profit of ₹10.27Cr a significant improvement.
The revenue for Q3 FY24 grew by 0.72% compared to the previous quarter.
The Selling, general & administrative expenses rose by 16.91% compared to the previous quarter and increased by 28.47% compared to the same period last year.
The operating income showed a strong growth of 26.39% compared to the previous quarter and increased by a whopping 435.11% compared to the same period last year.
The EPS (Earnings Per Share) for Q3 FY24 is ₹3.13, representing a remarkable increase of 413% compared to the previous year's same period.
Wanbury's stock performance has shown mixed results. It delivered a negative return of -1.2% in the last 1 week, a significant return of 168.48% in the last 6 months, and a modest return of 13.84% year-to-date.
Currently, Wanbury has a market capitalization of ₹469.9Cr and its 52-week high and low are ₹151 and ₹33.3 respectively.
Wanbury Financials
Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
---|---|---|---|---|---|
Total Revenue | 145.5 | 144.46 | +0.72% | 125.78 | +15.68% |
Selling/ General/ Admin Expenses Total | 24.63 | 21.07 | +16.91% | 19.17 | +28.47% |
Depreciation/ Amortization | 3.32 | 3.24 | +2.48% | 3.13 | +6.3% |
Total Operating Expense | 127.67 | 130.36 | -2.06% | 122.45 | +4.27% |
Operating Income | 17.82 | 14.1 | +26.39% | 3.33 | +435.11% |
Net Income Before Taxes | 10.26 | 7.19 | +42.72% | -3.04 | +436.84% |
Net Income | 10.27 | 7.36 | +39.53% | -3.28 | +413.5% |
Diluted Normalized EPS | 3.13 | 2.25 | +39.11% | -1 | +413% |
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
MoreLess